Presentation

Company Profile
Initiator Pharma is a Clinical Stage Life Science company. Its main asset IPED2015 represents a novel treatment paradigm for the treatment of Erectile Dysfunction (ED) and aims improve the quality of life for the growing number for patients (and their partners) that do not respond or cannot be treated with the current marketed medication. Initator Pharma targets the non-responders to PDE5i drugs (such as Viagra© and Cialis©), a potential market of around 100 million men in 2025 where current therapies offer very limited opportunities to maintain a normal sexual life. The company’s drug candidate IPED2015 exerts its action through a novel mechanism targeting central neurotransmitters and has the potential to reduce the side-effects of the current treatment.

Recent highlights
In April 2021 Initiator pharma announced that it had filed a Clinical Trial Application for its planned Phase II study with IPED2015 in organic erectile dysfunction patients. In June, the company announced that the CTA for a Phase 2b study with IP2015 was approved.

Outlook
Some of the company’s next objectives include:
• Complete Proof-of-concept in phase II study that IP2018
has effect on ED in patients with ED of psychogenic
origin
• Start Phase IIb study to examine the effect of IPED2015
on sexual intercourse and erectile dysfunction in patients
with ED of organic origin
• Start Proof-of-Principle Pain study in healthy subjects
IPTN2021 Program
• Start Phase 1 Multiple ascending Dose (MAD) Clinal
study IPTN2021